vs
Side-by-side financial comparison of Stoke Therapeutics, Inc. (STOK) and SILVERCORP METALS INC (SVM). Click either name above to swap in a different company.
SILVERCORP METALS INC is the larger business by last-quarter revenue ($223.8M vs $158.6M, roughly 1.4× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -1.3%, a 72.5% gap on every dollar of revenue.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
Silvercorp Metals Inc. (Silvercorp) is a Canadian-based, China-focused precious metals company engaged in the acquisition, exploration, and development of silver-containing properties.
STOK vs SVM — Head-to-Head
Income Statement — Q1 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $158.6M | $223.8M |
| Net Profit | $112.9M | $-2.9M |
| Gross Margin | — | — |
| Operating Margin | 70.2% | — |
| Net Margin | 71.2% | -1.3% |
| Revenue YoY | 3661.1% | — |
| Net Profit YoY | 528.0% | — |
| EPS (diluted) | $1.90 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $223.8M | ||
| Q2 25 | — | $72.2M | ||
| Q1 25 | $158.6M | — | ||
| Q4 24 | $22.6M | $172.5M | ||
| Q3 24 | — | $114.0M | ||
| Q2 24 | — | $60.0M | ||
| Q4 23 | — | $174.0M | ||
| Q3 23 | — | $115.3M |
| Q4 25 | — | $-2.9M | ||
| Q2 25 | — | $28.1M | ||
| Q1 25 | $112.9M | — | ||
| Q4 24 | $-10.5M | $42.1M | ||
| Q3 24 | — | $28.0M | ||
| Q2 24 | — | $13.2M | ||
| Q4 23 | — | $18.8M | ||
| Q3 23 | — | $3.9M |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 70.2% | — | ||
| Q4 24 | -60.4% | 30.5% | ||
| Q3 24 | — | 30.7% | ||
| Q2 24 | — | 30.0% | ||
| Q4 23 | — | 16.8% | ||
| Q3 23 | — | 10.4% |
| Q4 25 | — | -1.3% | ||
| Q2 25 | — | 39.0% | ||
| Q1 25 | 71.2% | — | ||
| Q4 24 | -46.4% | 24.4% | ||
| Q3 24 | — | 24.5% | ||
| Q2 24 | — | 22.0% | ||
| Q4 23 | — | 10.8% | ||
| Q3 23 | — | 3.4% |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $1.90 | — | ||
| Q4 24 | $-0.15 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | $0.11 | ||
| Q3 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.8M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $350.1M | — |
| Total Assets | $406.9M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $274.8M | — | ||
| Q4 24 | $128.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $350.1M | — | ||
| Q4 24 | $229.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $406.9M | — | ||
| Q4 24 | $271.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $131.8M | $107.9M |
| Free Cash FlowOCF − Capex | $131.7M | — |
| FCF MarginFCF / Revenue | 83.0% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.17× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $107.9M | ||
| Q2 25 | — | $40.0M | ||
| Q1 25 | $131.8M | — | ||
| Q4 24 | $-23.2M | $81.3M | ||
| Q3 24 | — | $57.7M | ||
| Q2 24 | — | $28.9M | ||
| Q4 23 | — | $79.9M | ||
| Q3 23 | — | $54.2M |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $131.7M | — | ||
| Q4 24 | $-23.2M | — | ||
| Q3 24 | — | $33.8M | ||
| Q2 24 | — | $17.0M | ||
| Q4 23 | — | $45.7M | ||
| Q3 23 | — | $31.5M |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 83.0% | — | ||
| Q4 24 | -102.7% | — | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 28.3% | ||
| Q4 23 | — | 26.2% | ||
| Q3 23 | — | 27.3% |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | — | 21.0% | ||
| Q2 24 | — | 19.8% | ||
| Q4 23 | — | 19.7% | ||
| Q3 23 | — | 19.7% |
| Q4 25 | — | — | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | 1.17× | — | ||
| Q4 24 | — | 1.93× | ||
| Q3 24 | — | 2.06× | ||
| Q2 24 | — | 2.19× | ||
| Q4 23 | — | 4.25× | ||
| Q3 23 | — | 13.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
